The CRISPR/cas9 system provides unique opportunities to test the efficacy of targeted therapies, investigate mechanisms of drug resistance, and to test newer immune-based therapeutic strategies for ALK rearranged lung cancer in preclinical in vivo models. The gene discussed is ALK; the disease is lung cancer.